Skip to main content
. Author manuscript; available in PMC: 2007 Oct 24.
Published in final edited form as: Am J Transplant. 2004 Sep;4(9):1475–1489. doi: 10.1111/j.1600-6143.2004.00526.x

Table 1.

Clinical and demographic data of patients entered into the study

Patient ID BX PBL Age Sex Immunosuppression Histopathology LD/CAD Scr (mg/dL) Days post TX
C1 • 38 Female 0.8
C2 • 42 Male 0.9
C3 • 35 Female 0.6
C4 • 39 Female 0.9
C5 • • 39 Male 1.2
C6 • 44 Male 0.8
C7 • 36 Male 1.2
C8 • 35 Female 0.8
C9 • 50 Female 0.6
AR1 • • 42 Male CsA/MMF/P BanffIIA CAD 12  285
AR2 • • 28 Male FK/MMF/P BanffIIA LD 5.9 1467
AR3 • • 18 Male CsA/MMF/P BanffIA CAD 2.2  119
AR4 • • 28 Female FK/MMF/P BanffIIA CAD 1.5  366
AR5 • • 26 Female CsA/MMF/P Borderline CAD 2  278
AR6 • • 55 Male SRL/MMF/P Borderline CAD 2.9   68
AR7 • • 35 Male SRL/MMF/P BanffIA CAD 2  184
TX1 • 51 Male CsA/MMF/P Normal CAD 1.5  932
TX2 • 56 Male CsA/MMF/P Normal LD 1.3  911
TX3 • 52 Male CsA/MMF/P Normal CAD 1.2  902
TX4 • 31 Female CsA/MMF/P Normal LD 1.1  651
TX5 • 53 Female CsA/MMF/P Normal LD 1.1  689
TX6 • 32 Male CsA/MMF/P Normal LD 1.6  776
TX7 • 46 Female CsA/MMF/P Normal CAD 1.2  713
TX8 • 61 Male CsA/MMF/P Normal CAD 0.9  733
TX9 • 44 Male CsA/MMF/P Normal LD 1.8  718
TX10 • 21 Male CsA/MMF/P Normal CAD 1.5  674
TXPBL1 • 38 Male CsA/MMF/P CAD 1.4  461
TXPBL2 • 57 Female FK/MMF/P LD 1.3   42
TXPBL3 • 65 Male CsA/MMF/P CAD 1.5  213
TXPBL4 • 65 Female FK/MMF/P CAD 0.8  246
TXPBL5 • 36 Female CsA/MMF/P CAD 1.1 1278
TXPBL6 • 68 Male CsA/MMF/ CAD 1.7  376
TXPBL7 • 39 Male SRL/MMF/P CAD 0.9   36
TXPBL8 • 61 Female CsA/MMF/P CAD 0.9 1491
TXPBL9 • 46 Male SRL/MMF/P LD 1.2   81
NR1 • • 55 Male CsA/MMF/P CNI toxicity LD 1.7  456
NR2 • • 38 Male FK/MMF/P CNI toxicity LD 2.3  155
NR3 • • 61 Male SRL/MMF/P ATN LD 5.2   11
NR4 • • 43 Male CsA/MMF/P CNI toxicity CAD 3.8  262
NR5 • • 35 Male CsA/MMF/P ATN CAD 6.3   16
NR6 • 35 Female FK/MMF/P CNI toxicity CAD 2.6   37
NR7 • 44 Male SRL/MMF/P ATN CAD 6.3   40
NR8 • • 22 Female FK/MMF/P FSGS LD 3.3   78
NR9 • 58 Male CsA/MMF/P ATN CAD 5   47

BX, biopsy; PBL, peripheral blood lymphocytes; CsA, cyclosporine; MMF, mycophenolate mofetil; P, prednisone; FK, tacrolimus; SRL, sirolimus; CAD, cadaveric; LD, live donor; Scr, serum creatinine; ATN, actute tubular necrosis; CNI, calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis.